Sp110
TRANSLATING EVIDENCE INTO QUALITY IN INFLAMMATORY BOWEL DISEASE
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions. This session will discuss how to translate clinical research into quality improvement initiatives leading to successful improvement in patient outcomes. Attendees will also be able to incorporate feedback to improve patient satisfaction as well as reimbursement strategies as well as improving healthcare for socially disadvantaged populations and women's health.
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions. This session will discuss how to translate clinical research into quality improvement initiatives leading to successful improvement in patient outcomes. Attendees will also be able to incorporate feedback to improve patient satisfaction as well as reimbursement strategies as well as improving healthcare for socially disadvantaged populations and women's health.
Presenter
Tracks
Related Products
REAL WORLD IMPLEMENTATION OF TREAT-TO-TARGET IN PATIENTS WITH IBD IN A LEARNING HEALTH SYSTEM: AN IBD QORUS COLLABORATIVE STUDY
BACKGROUND AND AIMS: A treat-to-target (TTT) strategy of striving for symptomatic and endoscopic remission is recommended for the management of inflammatory bowel diseases (IBD). Yet, real-world uptake of TTT strategies has been modest…
CLINICAL, SEROLOGIC, AND GENETIC FACTORS ASSOCIATED WITH DECREASED POST-OPERATIVE PROPHYLAXIS PERSISTENCE IN CROHN’S DISEASE (CD)
BACKGROUND: Cancer is a major cause of morbidity and mortality in persons with inflammatory bowel disease (IBD). We evaluated temporal trends and relative risks of intestinal and extra-intestinal cancers among persons with IBD and matched controls…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
LARGE SINGLE-CENTER STUDY CONFIRMS KNOWN NUDT15, TPMT, AND HLA ASSOCIATIONS WITH THIOPURINE-ASSOCIATED ADVERSE EVENTS AND REVEALS PLEIOTROPIC EFFECTS AT THESE LOCI FOR THIOPURINE ADVERSE DRUG REACTIONS.
INTRODUCTION: We aimed to investigate the relationship between consumption of ultra-processed foods (UPFs) and: 1) active symptomatic disease and 2) intestinal inflammation in a cohort of adults living with inflammatory bowel disease (IBD)…
